Biocartis Group N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOGF research report →
Price Chart
About the company
Biocartis Group N. V. is a molecular diagnostics firm dedicated to advancing clinical practice through innovative diagnostic solutions.
- CEO
- Roger Moody
- IPO
- 2021
- Employees
- 526
- HQ
- Mechelen, BE
Get TickerSpark's AI analysis on BIOGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $65.41M
- P/E
- -0.27
- PEG
- -0.00
- P/S
- 0.47
- P/B
- -0.58
- EV/EBITDA
- -2.81
- Div Yield
- 0.00%
- Gross Margin
- 48.16%
- Op Margin
- -81.85%
- Net Margin
- -113.74%
- ROE
- 203.74%
- ROIC
- -50.72%
Latest fiscal year · YoY change
- Revenue
- $57.48M+19.1%
- Gross Profit
- $27.68M+92.9%
- Op Income
- $-47,047,000
- Net Income
- $-65,381,000+8.5%
- EPS
- $-1.08+12.9%
- OCF Growth
- +31.7%
- FCF Growth
- +32.6%
- 52W High
- $0.66
- 52W Low
- $0.66
- 50D MA
- $0.66
- 200D MA
- $0.66
- Beta
- 1.39
- Avg Volume
- 0
No earnings-call transcripts are available for BIOGF yet.
No ownership data on file for BIOGF.
Our BIOGF coverage
Recent articles, reports, and earnings notes.
No research on BIOGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOGF report →